MCMehtap Cakir

Mehtap Cakir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mehtap Cakir has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    COVID-19 HASTALARINDA KORTİKOSTEROİD TEDAVİSİ: NE ZAMAN VE NASIL?

    by Münire Çakir, Mehtap Çakir

    Çin’in Wuhan şehrinde ilk vakanın görülmesinden bu yana COVID-19 dünyada 2,7 milyondan fazla insanın hayatını kaybetmesine neden olmuştur. COVID-19’a bağlı ölümün başlıca nedenleri ARDS, sepsis ve/veya septik şoktur. Hastalığın etkinliği kanıtlanmış bir tedavisi henüz mevcut değildir. COVID-19’a bağlı oluşan hiperinflamasyon ve sitokin fırtınasının kontrolünde sentetik kortikosteroidlerin etkili olabileceği düşünülmüş ve klinik çalışmalar bu grup ilaçların mortaliteyi ve mekanik ventilasyon ihtiyacını azaltmada etkili olduklarını göstermiştir. Dünya Sağlık Örgütü, ciddi ve kritik hastalarda kortikosteroidlerin kullanımını güçlü öneri ile desteklerken ciddi olmayan hastalıkta kullanımdan kaçınılmasına koşullu öneri getirmiştir. Bu öneriler, sekiz randomize kontrollü çalışmanın sonuçlarına dayanmaktadır. Şu ana kadar yapılan çalışmalarda, tedavide en sık tercih edilen kortikosteroid molekülü metilprednizolon olmakla birlikte, deksametazon, hidrokortizon ve diğer sentetik glukokortikoidler de kullanılmaktadır. Kortikosteroidlerin mortalite üzerine etkilerinin ortaya konulduğu çalışmalarda genellikle düşük-orta dozda ilaç kullanılmış olup doz karşılaştırmalarının yapıldığı prospektif çalışmalar literatürde henüz mevcut değildir. Kortikosteroid tedavisi ile ilgili çekincelerden biri, tedavinin viral klirens üzerine etkisidir. Düşük dozda kortikosteroidlerin viral klirens üzerine az etkileri olduğu ya da etkilerinin olmadığı bildirilmekle birlikte, yüksek doz uygulamaların viral klirens üzerine etkisi ve yine gecikmiş viral klirensin klinik önemi net değildir. Kortikosteroidlerin en sık yan etkileri olan hiperglisemi ve sekonder bakteriyel infeksiyonlar yönünden hastaların yakın takip edilmeleri ve ciddi-kritik COVID-19 hastalarında, kritik-hastalıkla ilişkili kortikosteroid yetmezliği de bulunabileceğinden, tedavinin dikkatlice kesilmesi büyük önem taşımaktadır. COVID-19 tedavisinde kullanılacak kortikosteroidlerin türü, ideal zamanlaması, dozu, diğer ilaçlarla birlikte kullanımı konularında ve oluşabilecek muhtemel yan etkiler açısından daha fazla araştırmaya gerek vardır.


  • The Effect of Hypothyroidism on Color Contrast Sensitivity: A Prospective Study

    by Mehtap Cakir, Banu Turgut Ozturk, Elif Turan, Gulsum Gonulalan, Ilker Polat, Kemal Gunduz

    Background: Thyroid hormone has been shown to control retinal cone opsin expression, the protein of color vision, in adult rodents. Objectives: The aim of this study was to evaluate the effect of hypothyroidism on color contrast sensitivity in adult overt hypothyroid patients. Methods: Thirty-eight overt hypothyroid (31 females, 7 males) subjects and 20 euthyroid (16 females, 4 males) controls were studied prospectively. Color vision examination was performed by Chromatest, a software program analyzing the tritan (blue-yellow) color contrast threshold (tritan CCT) and protan (red-green) color contrast threshold (protan CCT). Color contrast sensitivity analyses of hypothyroid subjects were performed on admission and after L-thyroxine treatment when biochemical euthyroidism was achieved. Results: After a median period of 90 (90-210) days, 24 (19 females, 5 males) patients were euthyroid and eligible for a second color vision examination. Baseline tritan CCT and protan CCT values were significantly higher in the hypothyroid group compared to euthyroid controls, which clinically translates into impaired color contrast sensitivity (p < 0.001 and p < 0.001, respectively). There was a significant decrease in tritan CCT (p = 0.002) and protan CCT (p < 0.001) values in the hypothyroid group after euthyroidism was achieved, which denotes improvement in color contrast sensitivity. Conclusions: It is a novel finding of the current study that color contrast sensitivity is impaired in hypothyroidism and significantly improves after euthyroidism is achieved.


  • Assessment of the Pituitary Function in Nasopharyngeal Carcinoma Patients Treated with Radiotherapy

    by Suleyman Hilmi Ipekci, Mehtap Cakir, Aysel Kiyici, Mehmet Artac

    Article published by the Endocrine Society Article published by the Endocrine Society

  • A Retrospective Evaluation of Papillary Thyroid Carcinoma Patients Followed in an Endocrinology Outpatient Clinic

    by Mustafa Sait Gonen, Suleyman Hilmi Ipekci, Mine Ozturk, Gulsum Gonulalan, Mehtap Cakir, Ahmet Kaya, Mustafa Kulaksizoglu, Faruk Aksoy, Mehmet Erikoglu, Gungor Tastekin, et al.

  • Serum CXCL10 levels and neuromuscular manifestations in patients with autoimmune thyroid diseases

    by Mehtap Cakir, Funda Levendoglu, Aysel Kiyici, Yasemin Coskun

    Serum C-X-C motif chemokine 10 (CXCL10) levels have been shown to be elevated in autoimmune thyroid diseases (AITD). This study sought to determine whether newly diagnosed AITD patients with neuromuscular findings had higher levels of CXCL10 than those without neuromuscular manifestations. A total of 80 patients were recruited to the study, which included treatment-naive hypothyroid Hashimoto's thyroiditis (n = 19) and hyperthyroid Graves' disease (GD; n = 21), euthyroid thyroid autoantibody-positive (n = 20) and -negative (n = 20) patients. All patients underwent a thorough sensorimotor and neuromuscular examination. Serum samples were kept in - 20°C for further CXCL10 measurements with ELISA. There was a significant difference with regard to serum CXCL10 levels only between GD and euthyroid thyroid autoantibody-negative patient groups [187(12-418) vs. 37.5(2-542) pg/ml, p < 0.05]. However, a comparison of newly diagnosed AITD patients with and without neuromuscular manifestations in terms of serum CXCL10 levels yielded no significant difference. When a correlation of existence of a neuromuscular manifestation and serum CXCL10 levels was evaluated, a significantly positive correlation was noted between carpal tunnel syndrome (CTS) and serum CXCL10 levels [207 (95-748) pg/ml in CTS-positive vs. 117 (2-977) pg/ml in CTS-negative patients, p < 0.05]. In this study, from a number of neuromuscular manifestations, only the existence of CTS correlated with significantly higher CXCL10 levels in the whole study group. Further studies with larger numbers of patients with autoimmune-based hyper- and hypothyroidism may better clarify the hypothesis regarding a relationship between serum CXCL10 levels and neuromuscular manifestations of AITD.


  • The molecular pathogenesis and management of bronchial carcinoids

    by Mehtap Cakir, Ashley Grossman, Md, BA BSc MD FRCP FMedSci

    (2011). The molecular pathogenesis and management of bronchial carcinoids. Expert Opinion on Therapeutic Targets: Vol. 15, No. 4, pp. 457-491. doi: 10.1517/14728222.2011.555403


  • Open Access

    Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathways

    by Mehtap Cakir, Dorota Dworakowska, Ashley Grossman

    Introduction The somatostatin receptor as a GPCR Anti‐tumour effects of somatostatin Post‐receptor signalling pathways Neuroendocrine tumours (NETs) may occur at many sites in the body although the majority occur within the gastroenteropancreatic axis. Non‐gastroenteropancreatic NETs encompass phaeochromocytomas and paragangliomas, medullary thyroid carcinoma, anterior pituitary tumour, broncho‐pulmonary NETs and parathyroid tumours. Like most endocrine tumours, NETs also express somatostatin (SST) receptors (subtypes 1–5) whose ligand SST is known to inhibit endocrine and exocrine secretions and have anti‐tumour effects. In the light of this knowledge, the idea of using SST analogues in the treatment of NETs has become increasingly popular and new studies have centred upon the development of new SST analogues. We attempt to review SST receptor (SSTR) biology primarily in neuroendocrine tissues, focusing on pituitary tumours. A full data search was performed through PubMed over the years 2000–2009 with keywords ‘somatostatin, molecular biology, somatostatin receptors, somatostatin signalling, NET, pituitary’ and all relevant publications have been included, together with selected publications prior to that date. SSTR signalling in non‐neuroendocrine solid tumours is beyond the scope of this review. SST is a potent anti‐proliferative and anti‐secretory agent for some NETs. The successful therapeutic use of SST analogues in the treatment of these tumours depends on a thorough understanding of the diverse effects of SSTR subtypes in different tissues and cell types. Further studies will focus on critical points of SSTR biology such as homo‐ and heterodimerization of SSTRs and the differences between post‐receptor signalling pathways of SSTR subtypes.


  • Open Access

    Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2 – clinical implications

    by Mehtap Cakir, Dorota Dworakowska, Ashley Grossman

    Introduction SSTR subtype tissue distribution and its relevance to tumour imaging and treatment Conclusions


  • Significant hyperkalemia and hyponatremia secondary to telmisartan/hydrochlorothiazide treatment

    by Mehtap Cakir

    The renin–angiotensin–aldosterone system (RAAS) has crucial importance in maintaining blood pressure; thus blockade of RAAS is an effective antihypertensive treatment choice. The final step in RAAS stimulation is aldosterone secretion by angiotensin II, which leads to increased renal tubular sodium absorption and potassium secretion. Angiotensin II receptor blockers (ARBs) allow blockade of RAAS by blocking binding of angiotensin II to the AT1 receptors. There are several fixed-dose combinations of ARBs with hydrochlorothiazide in the market, providing antihypertensive therapies with complimentary mechanisms of action. With such combinations, while ARB inhibits the vasoconstricting action and aldosterone-secreting effects of angiotensin II, hydrochlorothiazide affects the renal tubular mechanisms of electrolyte reabsorption and directly increases excretion of sodium and chloride in the distal tubule, and promotes water excretion. Also, hypokalemia, which may be triggered by increased urinary potassium loss induced by hydrochlorothiazide, is opposed by ARB use and hence ARB/hydrochlorothiazide combination is known to be safe in terms of potassium imbalance. In this case report, significant hyperkalemia and hyponatremia related to telmisartan/hydrochlorothiazide use in a diabetic patient has been presented.